Related Experiment Video
Updated: Mar 10, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.3K
RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines
Susanne Rauch1, Johannes Lutz1, Aleksandra Kowalczyk1
1CureVac AG, Paul-Ehrlich-Str. 15, 72076, Tübingen, Germany.
Methods in Molecular Biology (Clifton, N.J.)
|December 18, 2016
Summary
This study presents a novel method for creating stabilized messenger RNA (mRNA) vaccines with improved immune response using modified sequences and protamine complexation (RNActive® technology). These advancements address key challenges in mRNA vaccine development and evaluation.
Area of Science:
- Vaccinology
- Molecular Biology
- Biotechnology
Background:
- Developing effective messenger RNA (mRNA) vaccines faces challenges in mRNA stability and immunogenicity.
- Production and testing require specialized techniques.
Purpose of the Study:
- To describe the production of stabilized mRNA with enhanced immunogenicity.
- To detail methods for evaluating vaccine quality and immune response.
Main Methods:
- Utilizing conventional nucleotides with modifications to the mRNA sequence.
- Complexation of mRNA with protamine (RNActive® technology).
- Synthesis, purification, and comprehensive in vitro/in vivo evaluation.
Main Results:
- Successfully produced stabilized mRNA with enhanced immunogenicity.
- Established a panel of methods for quality and immunogenicity assessment.
Conclusions:
- The described methods offer a viable approach for developing robust mRNA vaccines.
- RNActive® technology enhances mRNA stability and immune stimulation potential.
